Preop Nivoulmab Plus Chemo ' a Quantum Leap ' in NSCLC Therapy Preop Nivoulmab Plus Chemo ' a Quantum Leap ' in NSCLC Therapy
Further data from the pivotal Checkmate 816 trial continue to support the combination of nivolumab with chemotherapy in the neoadjuvant setting for patients with resectable non –small cell lung cancer.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Health | Hematology | Lung Cancer | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Non-Small Cell Lung Cancer